文献速递肿瘤 PET/CT

proPSMA研究中经活检证实的中危至高危前列腺腺癌患者[68Ga]Ga-PSMA-11 PET/CT前列腺内低摄取的患病率及中期结局

Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study.
PubMed 文献 · J Nucl Med · 2025-05-01

在proPSMA研究302例经活检证实的前列腺癌患者中,10例(3.3%;95% CI,1.6%-6.0%)[68Ga]Ga-PSMA-11 PET/CT前列腺内SUVmax≤4且常规影像(CT和全身骨扫描)正常;中位随访30个月,接受根治性治疗的9例中1例(11%)在根治性前列腺切除术后18个月治疗失败,4例(44%)在随机分组后42个月随访时仍在试验中且无治疗失败证据。

要点

  • proPSMA研究中前列腺内低摄取(SUVmax≤4)患病率为3.3%(10/302;95% CI,1.6%-6.0%)。
  • 10例中PRIMARY评分阳性5例(50%),5例(50%)接受根治性前列腺切除术。
  • 接受根治性治疗的9例中1例(11%)在术后18个月治疗失败并接受转移灶定向治疗。

核心结论

  • proPSMA试验中,经活检证实的前列腺癌患者PSMA PET/CT前列腺内低摄取患病率低(3.3%),治疗失败不常见。

研究设计与样本

  • 在前瞻性proPSMA研究中筛选PSMA PET/CT前列腺内SUVmax≤4的患者,随访至随机分组后42个月。
  • PRIMARY评分由3名核医学医师评估并以共识确定。
  • 治疗失败定义为新发转移性疾病、生化复发或启动挽救治疗。

主要发现

  • 302例中10例(3.3%;95% CI,1.6%-6.0%)PSMA PET/CT前列腺内低摄取且常规影像(CT和全身骨扫描)正常。
  • 中位年龄66岁(四分位距,60.5-70.3岁);国际泌尿病理学会活检分级组3为5例、5为5例,未发现非典型组织学。
  • 中位前列腺特异性抗原水平5.1 ng/nL(四分位距,2.3-8.3 ng/nL);中位随访间隔30个月(四分位距,24-39个月)。
  • 5例接受多参数MRI,其中PI-RADS评分5为2例、4为1例、2为2例;PRIMARY评分阳性5/10例(50%)。
  • 10例中5例(50%)接受根治性前列腺切除术、4例(30%)接受根治性放疗、2例(20%)仅接受雄激素剥夺治疗。

关键数值与推荐

  • 前列腺内低摄取定义为PSMA PET/CT SUVmax≤4。
  • 治疗失败定义为新发转移性疾病、生化复发或启动挽救治疗。
  • PRIMARY评分由3名核医学医师共识判定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current prevalence of low intraprostatic uptake for staging prostate-specific membrane antigen (PSMA) PET ranges between 4.4% and 17% in retrospective studies. We aimed to define the prevalence and describe the outcomes of patients with low intraprostatic uptake on PSMA PET/CT in the prospective proPSMA study. Methods: We identified patients with an SUVmax of 4 or less on PSMA PET/CT in the proPSMA study. Patients were followed up until 42 mo after randomization. The PRIMARY score was evaluated by 3 nuclear medicine physicians, with the result determined by consensus. Treatment failure was defined as new metastatic disease, biochemical recurrence, or initiation of salvage therapy. Results: Ten of 302 (3.3%; 95% CI, 1.6%-6.0%) patients had low intraprostatic uptake on PSMA PET/CT and normal findings on conventional imaging (CT and whole-body bone scanning). The median age was 66 y (interquartile range, 60.5-70.3 y). International Society of Urological Pathologists biopsy grade group was 3 in 5 patients and 5 in 5 patients, with no atypical histology identified. The median prostate-specific antigen level was 5.1 ng/nL (interquartile range, 2.3-8.3 ng/nL). The median follow-up interval was 30 mo (interquartile range, 24-39 mo). Multiparametric MRI was performed on 5 patients, with Prostate Imaging-Reporting and Data System score 5 in 2 patients, 4 in 1 patient, and 2 in 2 patients. The PRIMARY score was positive in 5 of 10 (50%) patients. Five (50%), 4 (30%), and 2 (20%) of 10 patients received radical prostatectomy, definitive radiotherapy, and androgen deprivation therapy alone, respectively. Of the 9 (90%) patients who received definitive treatment, 1 (11%) experienced treatment failure at 18 mo after radical prostatectomy and received metastasis-directed therapy. Biochemical recurrence was nonevaluable in the single patient who received androgen deprivation therapy alone. At the 42-mo follow-up after randomization, 4 of 9 (44%) patients who received definitive therapy remained on trial-none of whom had evidence of treatment failure. No other patients had new metastatic disease or initiation of salvage therapy during follow-up. Conclusion: In the proPSMA trial, there was a low prevalence (3.3%) of low intraprostatic uptake on PSMA PET/CT in patients with biopsy-confirmed prostate cancer, and treatment failure was infrequent.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chen DC, Buteau JP, Emmett L, et al. Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study. J Nucl Med. 2025. PMID: 40147846. doi:10.2967/jnumed.124.268901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。